CtrlK
MRNA
NASDAQ
Biotechnology
$67.27
USD
+$7.52 (+12.59%)
Last close
Market Cap:
$23.67B
Volume:
14.4M
Previous Close
$59.75
Day Range
$59.23 - $69.28
52 Week Range
$22.28 - $67.74
Average Volume (10 Days)
10M
P/E Ratio
0.00
Dividend Yield
0.00%
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The company is headquartered in Cambridge, Massachusetts and currently employs 4,700 full-time employees. The company went IPO on 2018-12-07. The company is engaged in developing medicines across infectious disease vaccines, oncology therapeutics and rare disease therapeutics. Its platform incorporates advances across three components, mRNA, delivery, and the manufacturing process, to advance its medicines. Its products are Spikevax and mNEXSPIKE (its COVID vaccines), and mRESVIA (its vaccine against respiratory syncytial virus (RSV)). The company also has a diverse development pipeline that consists of 35 therapeutic and vaccine programs, six of which are in late-stage development. The company has regulatory filings under review for its seasonal flu+COVID vaccine (mRNA-1083) in Europe and Canada and for its seasonal flu vaccine (mRNA-1010) in the United States, Europe, Canada and Australia. Its rare disease programs are Propionic acidemia (mRNA-3927); Methylmalonic acidemia (mRNA-3705), and Cystic Fibrosis (mRNA-3692/VX-522).
CEO
Mr. Stephane Bancel
Headquaters
Cambridge, MASSACHUSETTS, US
Founded
2018
Employees
4,700
The FDA is reviewing Moderna's mFlusiva, an investigational mRNA-based flu vaccine, with a decision expected by August 5. If approved, it would mark the first mRNA flu vaccine and could be available for the 2026-2027 flu season, representing a major diversification beyond COVID-19 vaccines for the company.
0
0
Moderna reported first-quarter revenue of $389 million, significantly exceeding Wall Street's estimate of about $224 million, driven by stronger-than-expected COVID-19 vaccine sales in international markets. The company posted a net loss that widened due to a $900 million litigation settlement charge related to vaccine technology patents. Despite the loss, Moderna reaffirmed its 2026 revenue growth target of up to 10%.
0
0
EXEL
Exelixis Inc
$54.77
+2.9%
BIIB
Biogen Inc
$216.03
+7.0%
RVMD
Revolution Medicines Inc
$182.08
+2.2%
NTRA
Natera Inc
$261.91
+0.5%
